Allen Institute and NYSCF launch collaboration to create inclusive cellular models

Today, the Allen Institute for Cell Science and New York Stem Cell Foundation (NYSCF) announced a pioneering collaboration to address this critical issue, combining two cutting-edge technologies to create more inclusive cellular models for studying disease.

FDA Approves First Phosphate Absorption Inhibitor for CKD

The FDA approved the first-in-class phosphate absorption inhibitor tenapanor (Xphozah) to reduce serum phosphorus in chronic kidney disease (CKD) patients on dialysis, developer Ardelyx announced

October 19, 2023

A scaffolded vaccine approach for broader influenza protection

Most people who get the seasonal influenza vaccine – which contains strains of viruses from distinct virus subtypes – mount a strong immune response to

December 20, 2024

Landmark Bio, Galapagos sign deal for CAR-T cell therapy

Landmark Bio will manufacture clinical trial batches of Galapagos’ CAR-T cell therapies for haematology-oncology. Credit: Kateryna Kon / Shutterstock.com. Landmark Bio and Galapagos have signed

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.